608 related articles for article (PubMed ID: 32759996)
1. Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.
Camellino D; Matteson EL; Buttgereit F; Dejaco C
Nat Rev Rheumatol; 2020 Sep; 16(9):481-495. PubMed ID: 32759996
[TBL] [Abstract][Full Text] [Related]
2. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
Buttgereit F; Dejaco C; Matteson EL; Dasgupta B
JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619
[TBL] [Abstract][Full Text] [Related]
3. Polymyalgia Rheumatica and Giant Cell Arteritis.
Buttgereit F; Matteson EL; Dejaco C
JAMA; 2020 Sep; 324(10):993-994. PubMed ID: 32897333
[No Abstract] [Full Text] [Related]
4. Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis.
Matteson EL; Buttgereit F; Dejaco C; Dasgupta B
Rheum Dis Clin North Am; 2016 Feb; 42(1):75-90, viii. PubMed ID: 26611552
[TBL] [Abstract][Full Text] [Related]
5. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica.
De Miguel E; Karalilova R; Macchioni P; Ponte C; Conticini E; Cowley S; Tomelleri A; Monti S; Monjo I; Batalov Z; Klinowski G; Falsetti P; Kane DJ; Campochiaro C; Hočevar A
Ann Rheum Dis; 2024 Feb; 83(3):335-341. PubMed ID: 37932008
[TBL] [Abstract][Full Text] [Related]
6. Subclinical giant cell arteritis in polymyalgia rheumatica: Concurrent conditions or a common spectrum of inflammatory diseases?
Salvarani C; Padoan R; Iorio L; Tomelleri A; Terrier B; Muratore F; Dasgupta B
Autoimmun Rev; 2024 Jan; 23(1):103415. PubMed ID: 37625672
[TBL] [Abstract][Full Text] [Related]
7. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and management of giant cell arteritis and polymyalgia rheumatica: challenges, controversies and practical tips.
Mackie SL; Pease CT
Postgrad Med J; 2013 May; 89(1051):284-92. PubMed ID: 23355687
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis.
Emamifar A; Ellingsen T; Hermann AP; Hess S; Gerke O; Ahangarani Farahani Z; Syrak Hansen P; Jensen Hansen IM; Thye-Rønn P
Sci Rep; 2021 Mar; 11(1):6220. PubMed ID: 33737697
[TBL] [Abstract][Full Text] [Related]
10. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.
Dejaco C; Brouwer E; Mason JC; Buttgereit F; Matteson EL; Dasgupta B
Nat Rev Rheumatol; 2017 Oct; 13(10):578-592. PubMed ID: 28905861
[TBL] [Abstract][Full Text] [Related]
11. Primary Care Vasculitis: Polymyalgia Rheumatica and Giant Cell Arteritis.
Pioro MH
Prim Care; 2018 Jun; 45(2):305-323. PubMed ID: 29759126
[TBL] [Abstract][Full Text] [Related]
12. Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy.
Martinez-Taboada VM; Bartolome MJ; Fernandez-Gonzalez MD; Blanco R; Rodriguez-Valverde V; Lopez-Hoyos M
Rheumatology (Oxford); 2003 Sep; 42(9):1055-61. PubMed ID: 12730520
[TBL] [Abstract][Full Text] [Related]
13. Giant cell arteritis and polymyalgia rheumatica: an update.
González-Gay MA; Pina T
Curr Rheumatol Rep; 2015 Feb; 17(2):6. PubMed ID: 25618572
[TBL] [Abstract][Full Text] [Related]
14. Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica.
Braun N; Fritz P; Rieth A; Schroth W; Kimmel M; Biegger D; Zakim D; Alscher MD
J Rheumatol; 2009 Oct; 36(10):2269-76. PubMed ID: 19684157
[TBL] [Abstract][Full Text] [Related]
15. [Polymyalgia rheumatica and Giant Cell Arteritis - Update on Diagnosis and Therapy].
Becker M
Praxis (Bern 1994); 2020; 109(5):347-354. PubMed ID: 32233763
[TBL] [Abstract][Full Text] [Related]
16. Highlights in clinical medicine-Giant cell arteritis, polymyalgia rheumatica and Takayasu's arteritis: pathogenic links and therapeutic implications.
Solimando AG; Vacca A; Dammacco F
Clin Exp Med; 2022 Nov; 22(4):509-518. PubMed ID: 34741677
[TBL] [Abstract][Full Text] [Related]
17. Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica.
van Sleen Y; Graver JC; Abdulahad WH; van der Geest KSM; Boots AMH; Sandovici M; Brouwer E
Front Immunol; 2019; 10():1981. PubMed ID: 31507597
[TBL] [Abstract][Full Text] [Related]
18. Polymyalgia rheumatica and giant cell arteritis-three challenges-consequences of the vasculitis process, osteoporosis, and malignancy: A prospective cohort study protocol.
Emamifar A; Hess S; Gerke O; Hermann AP; Laustrup H; Hansen PS; Thye-Rønn P; Marcussen N; Svendstrup F; Gildberg-Mortensen R; Bang JC; Farahani ZA; Chrysidis S; Toftegaard P; Andreasen RA; le Greves S; Andersen HR; Olsen RN; Hansen IMJ
Medicine (Baltimore); 2017 Jun; 96(26):e7297. PubMed ID: 28658131
[TBL] [Abstract][Full Text] [Related]
19. Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis-prevalence and clinical approach.
Borresen SW; Thorgrimsen TB; Jensen B; Hilsted L; Bartels EM; Feldt-Rasmussen U; Locht H
Rheumatology (Oxford); 2020 Oct; 59(10):2764-2773. PubMed ID: 32031663
[TBL] [Abstract][Full Text] [Related]
20. Metabolic bone health considerations in giant cell arteritis and polymyalgia rheumatica.
Low C; Conway R
Womens Health (Lond); 2023; 19():17455057221147385. PubMed ID: 36627860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
